

**Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation**  
*the GLORIA-AF Registry Program*

GLORIA-AF Investigators

*Published in:*  
American Journal of Medicine

*DOI (link to publication from Publisher):*  
[10.1016/j.amjmed.2018.03.024](https://doi.org/10.1016/j.amjmed.2018.03.024)

*Creative Commons License*  
CC BY-NC-ND 4.0

*Publication date:*  
2018

*Document Version*  
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*  
GLORIA-AF Investigators (2018). Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: the GLORIA-AF Registry Program. *American Journal of Medicine*, 131(8), 945-955.  
<https://doi.org/10.1016/j.amjmed.2018.03.024>

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

**Take down policy**

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.

# Accepted Manuscript

Title: Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: the GLORIA-AF Registry Program

Author: Michał Mazurek, Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Kristina Zint, Lionel Riou França, Shihai Lu, Gregory Y.H. Lip, GLORIA-AF Investigators

PII: S0002-9343(18)30305-X

DOI: <https://doi.org/10.1016/j.amjmed.2018.03.024>

Reference: AJM 14608

To appear in: *The American Journal of Medicine*



Please cite this article as: Michał Mazurek, Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Kristina Zint, Lionel Riou França, Shihai Lu, Gregory Y.H. Lip, GLORIA-AF Investigators, Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: the GLORIA-AF Registry Program, *The American Journal of Medicine* (2018), <https://doi.org/10.1016/j.amjmed.2018.03.024>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Gender Differences in Antithrombotic Treatment For Newly Diagnosed Atrial Fibrillation: the GLORIA-AF Registry Program

Michał Mazurek MD, PhD,<sup>a,b</sup> Menno V. Huisman MD, PhD,<sup>c</sup> Kenneth J. Rothman DrPH,<sup>d</sup> Miney Paquette MSc,<sup>e</sup> Christine Teutsch MD,<sup>f</sup> Hans-Christoph Diener MD, PhD,<sup>g</sup> Sergio J. Dubner MD,<sup>h</sup> Jonathan L. Halperin MD,<sup>i</sup> Kristina Zint PhD,<sup>j</sup> Lionel Riou França PhD,<sup>j</sup> Shihai Lu PhD,<sup>k</sup> Gregory Y.H. Lip MD,<sup>a,l,\*</sup> on behalf of the GLORIA-AF Investigators

From the <sup>a</sup>Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; <sup>b</sup>Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Medical University, Silesian Centre for Heart Diseases, Zabrze, Poland; <sup>c</sup>Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands; <sup>d</sup>RTI Health Solutions, Research Triangle Institute, Research Triangle Park, North Carolina; <sup>e</sup>Department of Medicine, Boehringer Ingelheim, Burlington, Canada; <sup>f</sup>Department of Clinical Development and Medical Affairs, Boehringer Ingelheim Pharma GmbH und Co KG, Ingelheim, Germany; <sup>g</sup>Department of Neurology, University of Duisburg-Essen, Germany; <sup>h</sup>Clínica y Maternidad Suizo Argentina, Buenos Aires, Argentina; <sup>i</sup>Icahn School of Medicine at Mount Sinai, New York, New York; <sup>j</sup>Global Epidemiology Department, Boehringer Ingelheim, Ingelheim, Germany; <sup>k</sup>Biostatistics and Data Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States of America; <sup>l</sup>Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Running head: Gender-related anticoagulation in atrial fibrillation

### \*Corresponding Author

Professor GYH Lip

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom

Tel: +44 121 507 5080; E-mail: [g.y.h.lip@bham.ac.uk](mailto:g.y.h.lip@bham.ac.uk)

**Clinical Trial Registration:** <http://www.clinicaltrials.gov>. Unique identifier: NCT01468701

**Authorship:** All authors had access to the data and played a role in writing this manuscript.

**Highlights:**

- Effective stroke prevention in atrial fibrillation requires oral anticoagulation.
- Globally, similar proportions of women and men were prescribed oral anticoagulation.
- The decision to prescribe oral anticoagulation does not seem to be gender-dependant.
- Other non-gender risk factors play a predominant role in anticoagulation decision making.

**Abstract***Aims*

Data on gender differences in oral anticoagulation for stroke prevention in patients with atrial fibrillation are conflicting, largely limited to regional reports and Vitamin K antagonist (VKA) use. We aimed to analyze gender-specific anticoagulant prescription patterns early following the introduction of non-VKA oral anticoagulants (NOACs) in a large, global registry on atrial fibrillation.

*Methods and Results*

Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) is an international registry program involving patients with newly diagnosed atrial fibrillation (<3 months from arrhythmia onset). We used data from 15,092 consecutive patients (median age 71.0 years; women 45.5%) enrolled between 2011 and 2014. Globally, 79.7% women and 80.2% men were anticoagulated; the absolute between-gender difference in prevalence of anticoagulant use was -0.5% (95% CI, -1.8%, 0.8%). VKAs

were prescribed to 32.8% and 31.9% (NOACs 46.8% and 48.3%) of women and men, respectively. No confounder for the association between gender and anticoagulant prescription was identified. Between-gender differences in anticoagulant use (lower use in women compared with men by decreasing order of magnitude of the difference) were found for: CHA<sub>2</sub>DS<sub>2</sub>-VASc score=1; CHADS<sub>2</sub> score=0; previous bleeding; age <65 years; no history of hypertension; myocardial infarction; coronary artery disease; North America region; and specialist office setting.

### *Conclusion*

Globally, the prevalence of anticoagulant use is similar in women and men. The decision to prescribe oral anticoagulation seems to depend predominantly upon guideline-related differences in stroke risk stratification rather than on gender.

**Keywords:** Atrial Fibrillation, Oral Anticoagulation, Gender, GLORIA-AF

## Introduction

Atrial fibrillation increases the risk of stroke.<sup>1,2</sup> For reasons not entirely clear, thromboembolic risk is overall higher in women than in men.<sup>3–5</sup> Gender-specific arterial structure, alternations in blood flow and endothelial function, increased inflammatory and thrombogenic status are examples of the potential reasons for this difference.<sup>6,7</sup> Consequently, female gender has been incorporated into the stroke risk stratification scheme, *i.e.*, CHA<sub>2</sub>DS<sub>2</sub>-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack [TIA], vascular disease, age 65–74 years, sex category [female]).<sup>8</sup> The majority of guidelines for atrial fibrillation recommend that oral anticoagulation should be considered in patients with ≥1 non-gender related risk factors for stroke (*i.e.*, CHA<sub>2</sub>DS<sub>2</sub>-VASc ≥1 in men and CHA<sub>2</sub>DS<sub>2</sub>-VASc ≥2 in women).<sup>9–13</sup>

Despite these recommendations, published data indicate variability in anticoagulation by gender, ranging from a 50% lower uptake in women versus men to more prevalent anticoagulation in women.<sup>6,14–17</sup> Patients described in these reports were geographically clustered and the anticoagulant was largely confined to Vitamin K antagonists (VKAs). Here we present findings from Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), which provides a unique opportunity to assess contemporary anticoagulation uptake worldwide.<sup>18</sup> The Phase II data allow for analyses of early practice patterns following the introduction of non-VKA oral anticoagulants (NOACs). Our goal was to assess baseline antithrombotic treatment strategies in women versus men and identify potential gender-related gaps in treatment for stroke prevention.

## Methods

### *Study Design*

The design of GLORIA-AF has been published.<sup>18</sup> In short, GLORIA-AF is a large ongoing, prospective registry program enrolling patients with a diagnosis of new onset, non-valvular atrial fibrillation at risk for stroke. Inclusion criteria are: adult, newly diagnosed non-valvular atrial fibrillation (<3 months prior study enrolment), and  $\geq 1$  stroke risk factor in the CHA<sub>2</sub>DS<sub>2</sub>-VASc scale. The main exclusion criteria are mechanical heart valve or valvular disease with the need for surgical intervention, prior VKA therapy for any reason for >60 days, indications other than atrial fibrillation for anticoagulant use, reversible cause of arrhythmia and life expectancy <1 year.

Thromboembolic and bleeding risks were assessed based on CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED (hypertension, abnormal renal and liver function, stroke, bleeding, age  $\geq 65$  years, drugs or alcohol) scales, respectively.<sup>8,19</sup> Low-risk of stroke was defined by CHA<sub>2</sub>DS<sub>2</sub>-VASc=1 in women (men with CHA<sub>2</sub>DS<sub>2</sub>-VASc=0 were not recruited); moderate-risk were men with CHA<sub>2</sub>DS<sub>2</sub>-VASc=1; and high-risk were those with CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$ , irrespective of gender. Bleeding risk was defined as low (HAS-BLED score <3) or high (score  $\geq 3$ ).<sup>19</sup>

### *Data Collection and Timelines*

For collection, storing and assuring safety and confidentiality of data, a validated Electronic Data Capture System was employed. To monitor data quality, multiple edit checks, data quality reviews and on-site monitoring visits were arranged and local investigators were instructed on system functionality and requirements. This analysis is based on cross-sectional, baseline data of patients enrolled from 2011 through 2014 (Phase II of the program, after first NOACs availability).

### *Statistical Analysis*

The continuous variables were expressed as median (Q1, Q3), whereas categorical variables as frequencies and percentages. To investigate the absolute between-gender difference in anticoagulation prescription, both overall and within strata defined by covariates, a binomial regression analysis was employed.<sup>20</sup> Binomial regression allows direct estimation of the difference between proportions of males and females prescribed anticoagulants. The first step of the analysis was to screen out potential confounders for gender. The change-in-estimate method was applied to verify how much adjusting one covariate can change the coefficient (anticoagulant prescription difference) of gender using binomial regression. To be considered potential confounders requiring adjustment in subsequent multivariable analyses, covariates were required to change the gender coefficient by at least 10%.

The second step was to investigate the overall gender difference in anticoagulant prescription by multivariable binomial regression analysis including gender and all potential confounders found, if any, in the first step. The third step was to investigate the gender differences within strata defined by covariates of clinical relevance, as outlined in Table S2. The multivariable binomial regression analyses were performed, each with 2 risk factors (gender and another risk factor) and the interaction term, along with all potential confounders found, if any, in the first step, associated with prescription of anticoagulation against no anticoagulation.



Confidence intervals were based on likelihood ratio. Patients with missing values were excluded from the binomial regression analyses. Analyses were performed using SAS statistical software version 9.4 (SAS Institute, Inc., Cary, NC, USA).

## Results

Overall, 15,092 consecutive patients (45.5% women) were enrolled (Table 1). Women were older, with 45.8%  $\geq 75$  years, compared with 33.6% men. The prevalences of hypertension, hyperlipidemia, diabetes, previous stroke/TIA, abnormal kidney function, previous bleeding episode and cancer were similar in both genders. A quarter of men (24.8%) had coronary artery disease and 13.8% prior myocardial infarction, whereas for women the corresponding proportions were approximately 50% lower. Paroxysmal atrial fibrillation was more common in women (57.2%) than in men (50.1%), as was symptomatic arrhythmia (31.4% versus 25.5%, respectively).

Based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, low risk of stroke was observed in 4.8% of women (score=1; female with no additional stroke risk factors), and 95.2% were at high risk (score  $\geq 2$ ). Moderate risk of stroke (score=1) was observed in 21.4% of men and high risk (score  $\geq 2$ ) in 78.6% men (Table 2). Bleeding risk was unknown for 10.3% of women (men: 13.2%), low for 81.3% of women (men: 77.1%) and high for 8.4% of women (men: 9.7%), as assessed by the HAS-BLED score.

### *Confounders For Gender in the Oral Anticoagulation Prescription*

By the change-in-estimate method, because all covariates caused relatively small changes (less than 10%) for the coefficient of gender in the binomial regression, no covariate was

identified as a potential confounder that needed adjustment in subsequent analyses (Table S1).

#### *Antithrombotic Therapy in Women and Men*

Overall, 79.7% of women and 80.2% men were prescribed anticoagulants (Table 2), the absolute between-gender difference (women *versus* men) in anticoagulant use being  $-0.5\%$  (95% CI,  $-1.8\%$ ,  $0.8\%$ ) [Table S1]. Anticoagulant choice was similar between genders: 32.8% women and 31.9% men were prescribed VKAs (NOACs 46.8 % and 48.3%). Overall, 8.1% of women and 7.6% men were given no antithrombotic therapy, while aspirin was prescribed to 11.3% of both genders.

#### *Antithrombotic Therapy in Relation to Stroke and Bleeding Risks*

Antithrombotic therapies in relation to thromboembolic risk are presented in Figure 1, Panel A. For  $\text{CHA}_2\text{DS}_2\text{-VASc}=1$ , 46.1% of women and 69.8% of men were prescribed anticoagulants, whereas the corresponding proportions for  $\text{CHA}_2\text{DS}_2\text{-VASc}$  score  $\geq 2$  were 81.4% and 83.0%, respectively. Detailed treatment strategies according to stroke risk (as per  $\text{CHA}_2\text{DS}_2\text{-VASc}$  score 1-9) are presented in Figure 2, separately for women (Panel A) and men (Panel B).

Of the studied population, 18.3% of women and 17.0% men at low risk of bleeding (HAS-BLED score of 0-2) were not anticoagulated, whereas the corresponding proportions for those at high risk of hemorrhage (HAS-BLED  $\geq 3$ ) were 34.7% and 31.6%, respectively (Figure 1, Panel B). Aspirin was the most commonly prescribed antithrombotic drug in both women (28.3%) and men (27.1%) at high risk of bleeding.

### *Antithrombotic Treatment by Geographic Region*

Apart from evident between-region differences in overall anticoagulant use and choice of specific anticoagulant agents, oral anticoagulation by gender was similar within particular regions (Figure 3). The exception was noted in North America, where fewer women (75.9%) than men (80.4%) were anticoagulated. The corresponding proportions for anticoagulant use by females and males in other regions were as follows: 54.4 vs 55.8% in Asia; 89.9 vs 90.2% in Europe, 86.8 vs 84.1% in Latin America and 88.7 vs 86.3% for Africa/Middle East, respectively.

### *Gender Difference in Anticoagulation Prescription by Covariates*

Gender differences in oral anticoagulant prescription within strata defined by variables of clinical relevance and their interaction term associated with prescription of anticoagulation against no anticoagulation are presented in Figure 1, Panel C and Table S2. Between-gender (women *versus* men) differences in anticoagulant use were found for (by decreasing order of magnitude of the difference): CHA<sub>2</sub>DS<sub>2</sub>-VASc score=1; CHADS<sub>2</sub> score=0; previous bleeding; age <65 years; no history of hypertension; myocardial infarction; coronary artery disease; North America region; and specialist office setting.

## **Discussion**

The principal finding of our study is that globally similar proportions of women (79.7%) and men (80.2%) are prescribed oral anticoagulation for stroke prevention in atrial fibrillation. Second, oral anticoagulant choice is unaffected by gender (approximately 1/3 and 1/2 are prescribed VKAs and NOACs, respectively). Third, when exploring subgroups, the most

important difference in anticoagulant use identified between women and men is for patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1 (46.1% of women and 69.8% of men, respectively); this difference may be linked to guideline recommendations for atrial fibrillation, hence the decision to prescribe anticoagulation is not gender-dependent, but may rely predominately upon clinical stroke risk factors.

Although we found no confounders for the association between gender and anticoagulant use as well as global anticoagulation was nearly identical amongst women and men, we identified several factors of clinical relevance to interact with gender and anticoagulants prescription (*i.e.*, thromboembolic risk, previous bleeding, age, geographic region, health care setting, comorbid coronary artery disease, myocardial infarction or hypertension).

The largest between-gender difference in anticoagulant use (46.1% and 69.8% for women and men, respectively) was found for CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1. This reflects a different clinical approach to a score of 1 in both genders, rather than an underuse of anticoagulation in women compared with men. On the contrary, women with this score seem over-treated with anticoagulants. Indeed, past European guidelines (in effect during enrolment period for Phase II of GLORIA-AF, 2011-2014) as well as present guidelines in Europe state that women with CHA<sub>2</sub>DS<sub>2</sub>-VASc=1 (1 point for female gender only) are at “truly low-risk” for stroke and should not be anticoagulated as this brings no benefit but may cause harm.<sup>9-11</sup> By contrast, anticoagulation should be considered in patients with 1 non-gender related risk factors for stroke, that is CHA<sub>2</sub>DS<sub>2</sub>-VASc=1 for men and CHA<sub>2</sub>DS<sub>2</sub>-VASc=2 for women.<sup>9,10</sup> We observed similar proportions of women and men with one non-gender related risk factor being anticoagulated (71.9% and 69.1%, respectively).

A similar pattern (less anticoagulant use for women than men) was noted for those aged <65 years with no history of hypertension, which seems to reflect treatment strategy for low risk patients. We observed no between-gender differences for patients  $\geq 65$  years of age or with comorbid hypertension. Indeed, on the other side of the stroke risk continuum (high-risk cohort), as defined by the  $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$  (regardless of gender), we observed a similar anticoagulation by women and men, at 81.4% and 83.0%, respectively. Nonetheless, we found that fewer women than men were anticoagulated if they had a previous bleeding event, even though no major between-gender differences were noted with regard to bleeding risk, as per HAS-BLED scheme. The reasons for this disparity in anticoagulation patterns between men and women are not fully understood, but perhaps may reflect a differently perceived (higher in women) risk of bleeding complications in relation to gender. Importantly, the net clinical benefit of anticoagulation, when balancing stroke risk reduction versus increased risk of bleeding, is positive and even greater in patients at increased risk of bleeding.<sup>21,22</sup>

Regional disparities in anticoagulant use by gender may result from various guideline recommendations issued by different societies, largely due to different thresholds for anticoagulation initiation.<sup>23,24</sup> We found that fewer women than men were anticoagulated in North America. Our findings are consistent with recent report of the PINNACLE Registry, which found that in North America women are less likely to be anticoagulated.<sup>25</sup> Unlike European guidelines, the American recommendations offer OAC, aspirin or no stroke prophylaxis to patients with  $\text{CHA}_2\text{DS}_2\text{-VASc}=1$  (regardless of gender), whereas anticoagulation is recommended for those with the score  $\geq 2$ .<sup>11,26</sup> By considering female

gender as a risk factor for those with  $\text{CHA}_2\text{DS}_2\text{-VASc}=1$ , the American guidelines (in contrast to European guidelines) could potentially be recommending anticoagulation for women who may be at truly low risk for stroke (thus, potential drug overuse), whereas anticoagulants may be underused in men at moderate risk of stroke.<sup>24,27,28</sup> Although the difference in anticoagulation rates amongst women versus men in North America is modest, patients with one risk factor for stroke constitute only the minority of atrial fibrillation population, for example only 13.9% in the present analysis (and taking into account the fact that men with  $\text{CHA}_2\text{DS}_2\text{-VASc}=0$  were not recruited by GLORIA-AF). Importantly, though 1-year stroke rates in untreated patients with only 1 risk factor for stroke (beyond gender) vary amongst studies, the majority of reports show evident clinical benefit of anticoagulation versus no anticoagulation.<sup>24,27-30</sup> The same reports show also no benefit of anticoagulation in patients with no stroke risk factors, that is men with  $\text{CHA}_2\text{DS}_2\text{-VASc}=0$  and women with  $\text{CHA}_2\text{DS}_2\text{-VASc}=1$  (one point for female gender only).

In Canada, female gender is not perceived as a stroke risk factor and anticoagulation is recommended for patients with  $\text{CHADS}_2 \geq 1$  (Congestive Heart Failure, Hypertension, Age  $\geq 75$ , Diabetes, Stroke/TIA).<sup>31</sup> We observed no difference in anticoagulant use by gender for  $\text{CHADS}_2 \geq 1$ , but fewer women than men were anticoagulated if  $\text{CHADS}_2$  score was 0. In contrast to  $\text{CHA}_2\text{DS}_2\text{-VASc}$  scoring system, employment of  $\text{CHADS}_2$  scheme may underestimate the risk of stroke in patients categorized as low risk (score=0).<sup>32</sup> Indeed, in Canada, a woman age  $<65$  years with vascular disease is not recommended anticoagulation ( $\text{CHADS}_2=0$ ), whereas in Europe anticoagulation is considered/indicated ( $\text{CHA}_2\text{DS}_2\text{-VASc}=2$ ) for such women.<sup>9-12</sup> Importantly, women versus men with vascular disease (i.e. coronary

artery disease and prior myocardial infarction) in the present analysis were less likely to be anticoagulated.

A recent report from 3 nationwide registries suggests that female gender is a “stroke risk modifier” rather than a “stroke risk factor” and although stroke risk may be higher in women versus men it seems that “female gender” may be safely omitted in decision making on oral anticoagulation prescription.<sup>33</sup> Thus, use of a CHA<sub>2</sub>DS<sub>2</sub>-VA score (i.e. excluding gender criterion) may be considered.

### Limitations

Per study protocol, GLORIA-AF recruited patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 1$ . Thus, no data on males with score zero (low-risk of stroke) were available. Our analyses are based on the prescription of baseline anticoagulation in relation to gender, and thus we could assess neither quality of anticoagulation nor changes in practice patterns over time. Only patients with new onset atrial fibrillation (not all-comers) were recruited. Both patients and physicians knew they were participants of a registry program and patients could join the study only after signing an informed consent. This might have led to higher overall anticoagulation rates compared with general population.

In order to analyze many clinically important factors affecting decision making on anticoagulation prescription, we have performed a log-binomial analysis of anticoagulant use against no anticoagulant use, instead of analyzing the use of each of the anticoagulants separately. Also, we did not analyze the associations between anticoagulant use and concomitant dual antiplatelet therapy use by gender. A detailed analysis of various combinations of antiplatelet therapy use  $\pm$  anticoagulant use that may have varying

durations of use is beyond the scope of the current analysis that focuses on gender differences.

We used a 10% absolute change in the coefficient of gender as a cut-off for identification of confounders of the association between gender and anticoagulant use. More typically, a 10% relative change is used. We opted for an absolute cut-off because the effect of gender on anticoagulant use seems nearly null. The results would have been unchanged for any absolute change threshold above 2.3% (Table S1). With the threshold 2.3% (or any above 1.1%), the retained model would have adjusted for CHA<sub>2</sub>DS<sub>2</sub>-VASc score and the resulting absolute difference in anticoagulation between women and men would have shifted from -0.5% (95% CI -1.8, 0.8) to -2.8% (-4.0,-1.5) (Table S1), which would still support our principal finding that the oral anticoagulant use is globally similar between women and men. In addition, a model estimating the effect of gender when adjusting for all other factors has been reported;<sup>34</sup> the effect of gender on anticoagulation was not affected by the adjustments (relative risk of anticoagulant prescription for females compared with males: 0.99 unadjusted vs. 0.99 adjusted for all other factors). We have therefore no reason to suspect that our results were sensitive to this choice.

A few variables had non-negligible proportions of missing values. For example, creatinine clearance had 21% missing, HAS-BLED score had 12% missing, and alcohol abuse had 8% missing. Multiple imputation to deal with missing values was not planned in the phase II analyses, which are mostly descriptive, but this will be considered for phase III.

## Conclusion



Globally, the prevalence of anticoagulant use is similar in women and men. The decision to prescribe oral anticoagulation seems to depend predominantly upon guideline-related differences in stroke risk stratification rather than on gender.

Accepted Manuscript

**Funding**

This work was supported by Boehringer Ingelheim GmbH.

Accepted Manuscript

**Conflict of interest:**

M.M. declares no conflict of interest. M.V.H. has received honoraria for presentations and research grants from Boehringer Ingelheim, Bayer HealthCare, Pfizer, GlaxoSmithKline (GSK), and Actelion Pharmaceuticals. K.J.R. is an employee of RTI Health Solutions, an independent nonprofit research organization that does work for government agencies and pharmaceutical companies. H.C.D. has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Abbott, Allergan, AstraZeneca, Bayer Vital, BMS, Boehringer Ingelheim, CoAxia, Corimmun, Covidien, Daiichi-Sankyo, D-Pharm, Fresenius, GSK, Janssen-Cilag, Johnson & Johnson, Knoll, Lilly, MSD, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Schering-Plough, Servier, Solvay, St Jude, Syngis, Talecris, Thrombogenics, WebMD Global, Wyeth and Yamanouchi. Financial support for research projects was provided by AstraZeneca, GSK, Boehringer Ingelheim, Lundbeck, Novartis, Janssen-Cilag, Sanofi-Aventis, Syngis and Talecris. The Department of Neurology at the University Duisburg-Essen received research grants from the German Research Council (DFG), the German Ministry of Education and Research (BMBF), the European Union, the National Institutes of Health (NIH), the Bertelsmann Foundation, and the Heinz-Nixdorf Foundation; H.C.D. has no ownership interest and does not own stocks of any pharmaceutical company; within the past year H.C.D. served as the editor of *Aktuelle Neurologie*, *Arzneimitteltherapie*, *Kopfschmerznews*, *Stroke News*, as the co-editor of *Cephalalgia* and was on the editorial board of *Lancet Neurology*, *Stroke*, *European Neurology* and *Cerebrovascular Disorders*; H.C.D. chairs the Treatment Guidelines Committee of the German Society of Neurology and has contributed to the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) guidelines for the treatment of atrial fibrillation. S.J.D. has received consultancy fees for serving as a steering committee member for Boehringer Ingelheim. He also holds research grants from St Jude Medical. J.L.H. is currently conducting research sponsored by Boehringer Ingelheim as a member of the Executive Steering Committee for the GLORIA-AF Registry, and has received consulting fees from Bayer HealthCare, Janssen-Ortho-McNeil, and Pfizer for advisory activities involving the development of anticoagulant drugs. M.P., C.T., K.Z., L.R.F. and S.L. are employees of Boehringer Ingelheim. G.Y.H.L. has been a consultant for Bayer/Janssen, Astellas, Merck, Sanofi, Bristol-Myers Squibb (BMS)/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo. He has also been a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo.

## References

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation* 1998;**98**:946–952.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ V. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002;**113**:359–364.
3. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation: Analysis of 2012 Participants in the SPAF I III Clinical Trials. *Stroke* 1999;**30**:1223–1229.
4. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors in Atrial fibrillation (ATRIA) study. *Circulation* 2005;**112**:1687–1691.
5. Mikkelsen AP, Lindhardsen J, Lip GYH, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study. *J Thromb Haemost* 2012;**10**:1745–1751.
6. Cheng EY, Kong MH. Gender differences of thromboembolic events in atrial fibrillation. *Am J Cardiol* 2016;**117**:1021–1027.
7. Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. *Thromb Haemost* 2014;**111**:385–391.
8. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;**137**:263–272.
9. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar

- N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey J-Y, Ponikowski P, Rutten FH, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Vardas PE, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlof B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJM, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;**31**:2369–429.
10. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. *Europace* 2012;**14**:1385–413.
  11. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;**37**:2893-2962.
  12. Atrial Fibrillation: The Management of Atrial Fibrillation - PubMed - NCBI. at <<http://www.ncbi.nlm.nih.gov/pubmed/25340239>>. Accessed January 13, 2016.
  13. Ogawa S, Aonuma K, Tse HF, Huang D, Huang JL, Kalman J, Kamakura S, Nair M, Shin DG, Stiles M, Teo WS, Yamane T. The APhRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. *Journal of Arrhythmia* 2013;**29**:190–200.
  14. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. *Circulation* 2001;**103**:2365–2370.

15. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. *JAMA* 2012;**307**:1952–1958.
16. Dagres N, Nieuwlaet R, Vardas PE, Andresen D, Lévy S, Cobbe S, Kremastinos DT, Breithardt G, Cokkinos D V, Crijns HJGM. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. *J Am Coll Cardiol* 2007;**49**:572–577.
17. Lip GYH, Laroche C, Boriani G, Cimaglia P, Dan G-A, Santini M, Kalarus Z, Rasmussen LH, Popescu MI, Tica O, Hellum CF, Mortensen B, Tavazzi L, Maggioni AP. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. *Europace* 2015;**17**:24–31.
18. Huisman M V, Lip GYH, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K, Ackermann D, Clemens A, Bartels DB. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. *Am Heart J* 2014;**167**:329–334.
19. Pisters R, Lane DA, Nieuwlaet R, De Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. *Chest* 2010;**138**:1093–1100.
20. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. *Am J Epidemiol* 1986;**123**:174–184.
21. Olesen JB, Lip GYH, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a “real world” nationwide cohort study. *Thromb Haemost* 2011;**106**:739–749.
22. Potpara TS, Lip GYH. Oral anticoagulant therapy in atrial fibrillation patients at high

- stroke and bleeding risk. *Prog Cardiovasc Dis* 2015;**58**:177–194.
23. Camm AJ, Pinto FJ, Hankey GJ, Andreotti F, Hobbs FDR, John Camm A, Richard Hobbs FD, Csiba L, De Freitas GR, Goto S, Cantú C, Gonzalez-Zuelgaray J, Hacke W, Hu HH, Mantovani L, Yoon BW, Hu D, Sim KH. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. *Europace* 2015;**17**:1007–1017.
  24. Nielsen PB, Larsen TB, Skjøth F, Overvad TF LG. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. *Sci Rep* 2016;**6**:27410.
  25. Thompson LE, Maddox TM, Lei L, Grunwald GK, Bradley SM, Peterson PN, Masoudi FA, Turchin A, Song Y, Doros G, Davis MB, Daugherty SL. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR<sup>®</sup>) PINNACLE Registry. *J Am Heart Assoc* 2017;**6**:e005801.
  26. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation* 2014;**130**:e199-267.
  27. Lip GYH, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc score. *J Am Coll Cardiol* 2015;**65**:1385–1394.
  28. Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanov F, Babuty D, Lip GYH. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. *Chest* 2016;**149**:960–968.
  29. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GYH, Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the

- CHA2DS2-VASc Score (Beyond Sex) receive oral anticoagulation? *J Am Coll Cardiol* 2015;**65**:635–642.
30. Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. *J Am Coll Cardiol* 2015;**65**:225–232.
  31. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, McMurtry MS, Connolly S, Cox JL, Dorian P, Ivers N, Leblanc K, Nattel S, Healey JS. 2014 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation. *Can J Cardiol* 2014;**30**:1114–1130.
  32. Lip GYH, Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB. Atrial fibrillation patients categorized as “Not for Anticoagulation” According to the 2014 Canadian cardiovascular society algorithm are not “Low Risk.” *Can J Cardiol* 2015;**31**:24–28.
  33. Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. *Circulation* 2018;**8**:832-840.
  34. Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Lip GYH. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF Phase II Registry. *Thromb Haemost* 2017;**12**:2376-88.



## Legends

**Figure 1** Gender Differences in Antithrombotic Therapy Prescription by Stroke (Panel A) and Bleeding Risk (Panel B) and Covariates (Panel C)

ASA – aspirin; VKA – Vitamin K antagonists; Other – antiplatelets other than aspirin and combination of antithrombotic agents; HAS-BLED – missing values = 706 (10.3%) in women and 1083 (13.2%) in men

**Figure 2** Antithrombotic Treatment in Relation to Stroke Risk in Females (Panel A) and Males (Panel B)

ASA – aspirin; OAC – oral anticoagulant; Other – antiplatelets other than aspirin and combination of antithrombotic agents; N/A – not applicable in men

**Figure 3** Antithrombotic Treatment by Gender and Region

ASA – aspirin; NOAC - non-Vitamin K antagonist oral anticoagulants; VKA – Vitamin K antagonists; Other – antiplatelets other than aspirin and combination of antithrombotic agents

**Table 1** Baseline Characteristics

N (%) or median [Q1, Q3]	All n=15,092 (100%)	Women n=6872 (45.5%)	Men n= 8220 (54.5%)
<b>Patient characteristics</b>			
Age, years (median [Q1, Q3])	71.0 (64.0, 78.0)	73.0 (66.0, 80.0)	70.0 (62.0, 77.0)
<65 years	4064 (26.9)	1464 (21.3)	2600 (31.6)
65-74 years	5121 (33.9)	2261 (32.9)	2860 (34.8)
≥75 years	5907 (39.1)	3147 (45.8)	2760 (33.6)
Current-smoker	1428 (9.5)	320 (4.7)	1108 (13.5)
Past smoker	4376 (29.0)	1127 (16.4)	3249 (39.5)
Creatinine clearance [ml/min] (median [Q1, Q3])	73.5 (55.3, 97.0)	66.8 (50.4, 87.9)	80.4 (60.6, 103.9)
<b>Medical history</b>			
Hypertension	11255 (74.6)	5177 (75.3)	6078 (73.9)
Hyperlipidemia	6026 (39.9)	2671 (38.9)	3355 (40.8)
Diabetes mellitus	3487 (23.1)	1472 (21.4)	2015 (24.5)
Previous stroke/TIA	2147 (14.2)	1008 (14.7)	1220 (14.8)
Congestive heart failure	3647 (24.2)	1419 (20.6)	2228 (27.1)
Ejection fraction <40% <sup>a</sup>	1388 (38.1)	370 (26.1)	1018 (45.7)
Coronary artery disease	3068 (20.3)	1029 (15.0)	2039 (24.8)
Myocardial infarction	1600 (10.6)	464 (6.8)	1136 (13.8)
Peripheral artery disease	475 (3.1)	130 (1.9)	345 (4.2)
Chronic gastrointestinal diseases	1976 (13.1)	960 (14.0)	1016 (12.4)
Abnormal kidney function <sup>b</sup>	241 (1.6)	80 (1.2)	161 (2.0)
Previous bleeding event	842 (5.6)	382 (5.6)	460 (5.6)
Alcohol abuse, ≥8 units/week	996 (6.6)	158 (2.3)	838 (10.2)
Cancer	1401 (9.3)	619 (9.0)	782 (9.5)
<b>Type of AF</b>			
Paroxysmal	8052 (53.4)	3931 (57.2)	4121 (50.1)
Persistent	5362 (35.5)	2224 (32.4)	3138 (38.2)
Permanent	1678 (11.1)	717 (10.4)	961 (11.7)
<b>Categorization of AF</b>			
Symptomatic	4263 (28.2)	2157 (31.4)	2106 (25.6)
Minimally Symptomatic	6004 (39.8)	2896 (42.1)	3108 (37.8)
Asymptomatic	4825 (32.0)	1819 (26.5)	3006 (36.6)

<b>Interventions in AF</b>			
AF cardioversion	2431 (16.1)	1084 (15.8)	1347 (16.4)
AF ablation	161 (1.1)	61 (0.9)	100 (1.2)
<b>Health-care setting</b>			
GP/primary care	968 (6.4)	451 (6.6)	517 (6.3)
Specialist office	4567 (30.3)	2034 (29.6)	2533 (30.8)
Community hospital	3969 (26.3)	1870 (27.2)	2099 (25.6)
University hospital	5081 (33.7)	2286 (33.3)	2795 (34.0)
Outpatient health care center	239 (1.6)	113 (1.6)	126 (1.5)
Anticoagulation clinic	142 (0.9)	60 (0.9)	82 (1.0)
Other	126 (0.8)	58 (0.8)	68 (0.8)
<b>Region</b>			
Region 1 – Asia	3071 (20.3)	1337 (43.5)	1734 (56.5)
Region 2 – Europe	7108 (47.1)	3317 (46.7)	3791 (53.3)
Region 3 – North America	3403 (22.5)	1524 (44.8)	1879 (55.2)
Region 4 – Latin America	913 (6.0)	410 (44.9)	503 (55.1)
Region 5 – Africa/Middle East	597 (4.0)	284 (47.6)	313 (52.4)

AF = atrial fibrillation; GP = general practitioner; SD = standard deviation; TIA = transient ischemic attack

<sup>a</sup>For patients with congestive heart failure

<sup>b</sup>Defined as the presence of chronic dialysis or renal transplantation or serum creatinine  $\geq 200$   $\mu\text{mol/L}$

Unknown/missing values: 1188 for alcohol abuse, 565 for smoking status, 440 for hyperlipidemia, 243 for abnormal kidney function, 15 for physician specialty, 941 for medical reimbursement, 2 for TIA/stroke, 411 for coronary artery disease, 9 for myocardial infarction, 149 for congestive heart failure, 36 for hypertension, 133 for peripheral artery disease, 117 for cancer, 172 for chronic gastrointestinal diseases, 276 for prior bleeding, 220 for AF cardioversion, 145 for AF ablation, 3221 missing for creatinine clearance.

**Table 2** Thromboembolic/Bleeding Risk and Antithrombotic Therapy by Gender

N (%) or median [Q1, Q3]	All n=15,092 (100%)	Women n=6872 (45.5%)	Men n= 8220 (54.5%)
<b>CHADS<sub>2</sub> (median [Q1, Q3])</b>	2.0 (1.0, 3.0)	2.0 (1.0, 3.0)	2.0 (1.0, 2.0)
Low Risk (score 0)	1221 (8.1)	730 (10.6)	491 (6.0)
Moderate Risk (score 1)	5150 (34.1)	2086 (30.4)	3064 (37.3)
High Risk (score≥2)	8719 (57.8)	4055 (59.0)	4664 (56.7)
Missing data	2 (0.0)	1 (0.0)	1 (0.0)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VAsC (median [Q1, Q3])</b>	3.0 (2.0, 4.0)	4.0 (3.0, 5.0)	3.0 (2.0, 4.0)
Low Risk (score 1 in women)	332 (2.2)	332 (4.8)	-
Moderate Risk (score 1 in men)	1761 (11.7)	-	1761 (21.4)
High Risk (score≥2)	12999 (86.1)	6540 (95.2)	6459 (78.6)
<b>HAS-BLED (median [Q1, Q3])</b>	1.0 (1.0, 2.0)	1.0 (1.0, 2.0)	1.0 (1.0, 2.0)
Low Risk (score 0-2)	11927 (79.0)	5590 (81.3)	6337 (77.1)
High Risk (score≥3)	1376 (9.1)	576 (8.4)	800 (9.7)
Missing Data	1789 (11.9)	706 (10.3)	1083 (13.2)
<b>Antithrombotic Therapy</b>			
None	1182 (7.8)	558 (8.1)	624 (7.6)
ASA	1706 (11.3)	774 (11.3)	932 (11.3)
VKA	4878 (32.3)	2255 (32.8)	2623 (31.9)
NOAC	7187 (47.6)	3219 (46.8)	3968 (48.3)
Dabigatran	4767 (31.6)	2122 (30.9)	2645 (32.2)
Rivaroxaban	1726 (11.4)	761 (11.1)	965 (11.7)
Apixaban	694 (4.6)	336 (4.9)	358 (4.4)
Other	139 (0.9)	66 (0.9)	73 (0.9)
Overall oral anticoagulation	12065 (79.9)	5474 (79.7)	6591 (80.2)

ASA = aspirin; NOAC = non-Vitamin K antagonist oral anticoagulants; VKA = Vitamin K antagonists; Other = antiplatelets other than aspirin and combination of anticoagulant agents; SD = standard deviation

Unknown/missing values: 2 for CHADS<sub>2</sub> score class, 1786 for HAS-BLED risk score class.

**Table S1** Binomial Regression Analysis to Select Confounding Variables For Gender Analysis Using Change-in-Estimate Method with 0.10 cut-off For Absolute Change – Dependent Variable in the Models is the Proportion of OAC Prescription (VKA, NOAC)

Gender models	Gender difference of OAC prescription coefficient of sex % (95% CI)	Absolute change in estimate of sex coefficient
No adjustment for other variable	-0.5 (-1.8, 0.8)	0.0
Adjustment of Age	-1.2 (-2.4, 0.1)	0.7
Adjustment of Type of AF	0.2 (-1.0, 1.4)	0.7
Adjustment of Categorization of AF	-0.4 (-1.7, 0.8)	0.1
Adjustment of AF cardioversion	-0.5 (-1.8, 0.8)	0.0
Adjustment of Hypertension	-0.3 (-1.6, 0.9)	0.2
Adjustment of Diabetes mellitus	-0.4 (-1.7, 0.8)	0.1
Adjustment of Previous stroke/TIA	-0.5 (-1.7, 0.8)	0.0
Adjustment of Congestive heart failure	-0.5 (-1.8, 0.8)	0.0
Adjustment of Coronary artery disease	-1.0 (-2.3, 0.3)	0.5
Adjustment of Myocardial infarction	-0.7 (-2.0, 0.6)	0.2
Adjustment of Peripheral artery disease	-0.4 (-1.7, 0.9)	0.1
Adjustment of Previous bleeding events	-0.4 (-1.7, 0.9)	0.1
Adjustment of Creatinine clearance <60ml/min	-0.2 (-1.6, 1.3)	0.3
Adjustment of Alcohol abuse	-1.0 (-2.4, 0.3)	0.5
Adjustment of Cancer	-0.5 (-1.7, 0.8)	0.0
Adjustment of Chronic gastrointestinal diseases	-0.4 (-1.7, 0.8)	0.1
Adjustment of No coverage for medications	-0.9 (-2.2, 0.4)	0.4
Adjustment of CHADS <sub>2</sub>	0.1 (-1.1, 1.4)	0.6
Adjustment of CHA <sub>2</sub> DS <sub>2</sub> -VASc	-2.8 (-4.0, -1.5)	2.3
Adjustment of HAS-BLED	-1.6 (-3.0, -0.3)	1.1
Adjustment of Region	-0.7 (-1.9, 0.4)	0.2
Adjustment of Type of site	-0.5 (-1.8, 0.7)	0.0
Adjustment of Physician specialty	-0.6 (-1.9, 0.7)	0.1

For abbreviations and unknown/missing values please refer to footnotes of Table 1-2; 12 patients who were prescribed a combination of OACs and patients with unknown/missing values were excluded from the binomial regression analyses.

**Table S2** Multivariable Analysis For Gender Differences by Covariates – Binomial Regression Analysis with 2 Risk Factors (Gender and Another Risk Factor) and Their Interaction Term Associated with Prescription of OAC against No OAC

Strata defined by covariates		Men Number of pts (on OAC/total)	Women Number of pts (on OAC/total)	Gender difference of OAC prescription (Reference = Male; %, 95% CI)
Age category				
	<65 years	1974/2599	1013/1462	-6.7 (-9.5, -3.8)
	65-74 years	2332/2859	1837/2259	-0.2 (-2.4, 1.9)
	≥75 years	2285/2757	2624/3144	0.6 (-1.3, 2.5)
Type of AF				
	Paroxysmal	3085/4117	2952/3927	0.2 (-1.7, 2.1)
	Persistent	2626/3137	1864/2221	0.2 (-1.8, 2.2)
	Permanent	880/961	658/717	0.2 (-2.5, 2.9)
Categorization of AF				
	Symptomatic	1704/2106	1784/2155	1.9 (-0.4, 4.2)
	Minimally Symptomatic	2455/3106	2244/2894	-1.5 (-3.6, 0.6)
	Asymptomatic	2432/3003	1446/1816	-1.4 (-3.7, 1.0)
AF cardioversion				
	No	5379/6738	4526/5695	-0.4 (-1.8, 1.1)
	Yes	1109/1347	876/1080	-1.2 (-4.3, 1.9)
Hypertension				
	No	1648/2118	1197/1682	-6.6 (-9.4, -3.8)
	Yes	4927/6073	4265/5171	1.3 (-0.1, 2.8)
Diabetes mellitus				
	No	4909/6203	4270/5394	0.0 (-1.5, 1.5)
	Yes	1682/2012	1204/1471	-1.7 (-4.3, 0.8)
Previous stroke/TIA				
	No	5612/7035	4675/5898	-0.5 (-1.9, 0.9)
	Yes	978/1179	799/966	-0.2 (-3.4, 3.0)
Congestive heart failure				
	No	4697/5898	4281/5388	-0.2 (-1.7, 1.3)
	Yes	1830/2228	1142/1417	-1.5 (-4.1, 1.1)
Coronary artery disease				
	No	4835/5964	4565/5640	-0.1 (-1.6, 1.3)
	Yes	1575/2038	736/1027	-5.6 (-8.9, -2.3)
Myocardial infarction				
	No	5693/7072	5137/6401	-0.2 (-1.6, 1.1)
	Yes	892/1135	336/463	-6.0 (-10.7, -1.3)
Peripheral artery disease				
	No	6224/7776	5343/6697	-0.3 (-1.6, 1.1)

	Yes	284/344	101/130	-4.9 (-13.1, 3.3)
Previous bleeding events				
	No	6074/7588	5103/6375	-0.0 (-1.3, 1.3)
	Yes	368/460	278/382	-7.2 (-13.0, -1.5)
Creatinine clearance <60ml/min				
	No	3917/4849	2627/3312	-1.5 (-3.2, 0.3)
	Yes	1210/1549	1737/2149	2.7 ( 0.1, 5.4)
Alcohol abuse				
	No	5343/6639	4973/6259	-1.0 (-2.4, 0.4)
	Yes	683/838	127/157	-0.6 (-7.3, 6.1)
Cancer				
	No	5882/7369	4915/6197	-0.5 (-1.9, 0.9)
	Yes	648/781	512/617	0.0 (-4.0, 4.0)
Chronic gastrointestinal diseases				
	No	5690/7106	4640/5828	-0.5 (-1.8, 0.9)
	Yes	814/1016	765/958	-0.3 (-3.8, 3.3)
No reimbursement for medications				
	No	5758/7123	4746/5940	-0.9 (-2.3, 0.4)
	Yes	443/591	363/485	-0.1 (-5.3, 5.1)
CHADS <sub>2</sub> score				
	Score 0	348/491	442/729	-10.2 (-15.6, -4.9)
	Score 1	2339/3064	1637/2085	2.2 (-0.1, 4.5)
	Score ≥2	3903/4659	3395/4050	0.1 (-1.5, 1.6)
CHA <sub>2</sub> DS <sub>2</sub> -VASc score				
	Score 1	1230/1761	153/332	-23.8 (-29.5, -18.0)
	Score ≥2	5361/6454	5321/6533	-1.6 (-2.9, -0.3)
HAS-BLED score				
	Score 0-2	5227/6332	4528/5586	-1.5 (-2.9, -0.1)
	Score ≥3	520/800	353/576	-3.7 (-8.9, 1.5)
Region				
	Region 1 - Asia	967/1734	727/1337	-1.4 (-4.9, 2.2)
	Region 2 - Europe	3421/3790	2983/3313	-0.2 (-1.6, 1.2)
	Region 3 - North America	1510/1875	1156/1521	-4.5 (-7.3, -1.7)
	Region 4 - Latin America	423/503	356/410	2.7 (-1.8, 7.3)
	Region 5 - Africa/Middle East	270/313	252/284	2.5 (-2.8, 7.8)
Type of site				
	Primary care	383/517	327/451	-1.6 (-7.2, 4.0)
	Specialist office	2050/2530	1584/2032	-3.1 (-5.4, -0.7)
	Community hospital	1804/2099	1607/1867	0.1 (-2.0, 2.3)
	University hospital	2106/2793	1744/2284	1.0 (-1.4, 3.3)
	Outpatient health care center	112/126	102/113	1.4 (-6.4, 9.1)

Physician specialty	Anticoagulation clinic	74/82	56/60	3.1 (-5.9, 12.1)
	Other	62/68	54/58	1.9 (-7.5, 11.3)
	GP/Geriatrician	148/198	122/161	1.0 (-7.9, 10.0)
	Cardiologist	6066/7576	4989/6275	-0.6 (-1.9, 0.8)
	Neurologist	71/77	57/70	-10.8 (-21.7, 0.1)
	Internist	137/174	119/148	1.7 (-7.2, 10.5)
	Other	160/181	181/205	-0.1 (-6.5, 6.3)

For abbreviations and unknown/missing values please refer to footnotes of Table 1-2; 12 patients who were prescribed a combination of OACs and patients with unknown/missing values were excluded from the binomial regression analyses.






Figure 1.tif




Figure 2.tif




Figure 3.tif